Impax Laboratories (IPXL) Shares are Up 7.5%

Impax Laboratories (IPXL) has been under a strong bear grip, hence the stock is down -23.59% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 7.54% in the past 1 week. The stock has risen by 7.5% in the past week indicating that the buyers are active at lower levels, but the stock is down -23.29% in the past 4 weeks.

Impax Laboratories Inc. has dropped 27.03% during the last 3-month period . Year-to-Date the stock performance stands at -45.39%. The stock has recorded a 20-day Moving Average of 15.75% and the 50-Day Moving Average is 20.49%.


Impax Laboratories (NASDAQ:IPXL): The stock opened at $23.53 on Friday but the bulls could not build on the opening and the stock topped out at $23.53 for the day. The stock traded down to $23.00 during the day, due to lack of any buying support eventually closed down at $23.35 with a loss of -0.85% for the day. The stock had closed at $23.55 on the previous day. The total traded volume was 569,766 shares.

Also, Equity Analysts at the Brokerage Firm, Northland Securities, upgrades their rating on the shares of Impax Laboratories (NASDAQ:IPXL). Northland Securities has a Outperform rating on the shares. Previously, the analysts had a Market Perform rating on the shares. The rating by the firm was issued on August 15, 2016.

Impax Laboratories, Inc. is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. The Company operates in two segments: Impax Generics and Impax Specialty Pharma. The Impax Generics is focused on the development, manufacture, sale and distribution of the Companys generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are marketed under their established drug names. The Impax Specialty Pharma is engaged in the development of brand pharmaceutical products for the treatment of central nervous system (CNS) disorders. The Impax Specialty Pharma is also engaged in the sale and distribution of Zomig (zolmitriptan) products, indicated for the treatment of migraine headaches.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.